Introduction MBiotec GmbH is a company that focuses on creating therapeutic substances for the treatment of pancreatic cancer. Their approach involves developing toll-like receptor agonists and compounds that stimulate the innate immune system, which in turn triggers the adaptive immune system to break immunological tolerance to cancer cells. The company's clinical development programs encompass substance analysis, laboratory testing, preclinical and clinical research, and drug commercialization and distribution. Founded in 2008, MBiotec GmbH is headquartered in Seefeld, Germany. |